International Journal of Molecular Sciences · 11 authors, 4 centres
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
A doxycycline-regulated gene therapy delivering a potassium channel (TREK-M) was injected into the hippocampus of kindled rats. While doxycycline activation effectively reduced spontaneous seizures by over 90%, baseline expression of the therapy in GABAergic inhibitory neurons itself caused seizures.
This preclinical study used male rats subjected to electrical kindling to model temporal lobe epilepsy. Researchers injected an adeno-associated viral (AAV) vector containing a doxycycline-regulated, engineered potassium channel (TREK-M) into the hippocampus. The central result was that treating epileptic rats with doxycycline reduced the frequency of spontaneous recurring seizures by more than 90%. However, a key side effect was that even low, doxycycline-independent expression of TREK-M in GABAergic inhibitory neurons was sufficient to cause spontaneous seizures. The study's strength lies in its use of a clinically translatable, regulatable gene therapy and comprehensive side effect testing. The findings highlight that drug-inducible gene therapies can be effective but require careful evaluation of off-target expression in inhibitory neurons to avoid pro-epileptic effects.
